The landscape of obesity management and metabolic health has been reshaped by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists; This review aims to delve into the current data surrounding semaglutide and other GLP-1 receptor agonists, examining their benefits, the quality of evidence behind various claims, and the broader implications of their use.
